Pharmasyntez invests 20 billion rubles in production in the Kaluga region
[ad_1]
Pharmasyntez-Kaluga (part of the Group of Companies “Pharmasynthesis”) and the Kaluga Region within the framework of the St. Petersburg Economic Forum (SPIEF) signed three agreements with a total value of more than 20 billion rubles. on investments in the creation and development of drug production in the region. This was reported in a press release of the Civil Code (available to Vedomosti).
The documents were signed by Governor Vladislav Shapsha and Vice President for Government Relations of the State Corporation “Pharmasynthesis» Oleg Astafurov.
According to the agreements, by 2026 the pharmaceutical company will launch a complex for the production of pharmaceutical substances in the Vorotynsk industrial park, including for the production of oncological drugs. The capacity of the enterprise will be up to 1 thousand tons of substances per year. In addition, Pharmasyntez will build a plant for the production of finished medicines in the region.
The Pharmasyntez Group of Companies, founded in 1997, is one of the largest domestic pharmaceutical manufacturers. The company is owned by Vikram Punia. Pharmasyntez produces anticancer, hormonal, antiviral and other drugs. The company’s plants are located in Ussuriysk, Irkutsk, Bratsk, Tyumen and St. Petersburg. At the end of 2022 the consolidated revenue of the Group of Companies amounted to 43 billion rubles.
[ad_2]
Source link
